Profound Medical Corp (PRN) - Total Liabilities

Latest as of March 2026: CA$19.58 Million CAD ≈ $14.17 Million USD

Based on the latest financial reports, Profound Medical Corp (PRN) has total liabilities worth CA$19.58 Million CAD (≈ $14.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Profound Medical Corp annual equity growth to track the company's year-over-year net asset growth rate.

Profound Medical Corp - Total Liabilities Trend (2014–2025)

This chart illustrates how Profound Medical Corp's total liabilities have evolved over time, based on quarterly financial data.

Profound Medical Corp Competitors by Total Liabilities

The table below lists competitors of Profound Medical Corp ranked by their total liabilities.

Company Country Total Liabilities
Grupo Ecoener S.A.
MC:ENER
Spain €688.31 Million
Albatron Technology Co Ltd
TWO:5386
Taiwan NT$701.16 Million
Enel Generacion Costanera SA
BA:CECO2
Argentina AR$102.36 Billion
Peach Property Group AG
SW:PEAN
Switzerland CHF1.17 Billion
Suzhou Jin Hong Shun Auto Parts Co Ltd Class A
SHG:603922
China CN¥305.98 Million
Arbonia AG
SW:ARBN
Switzerland CHF372.12 Million
Shenzhen Ruihe Construction Decoration Co Ltd
SHE:002620
China CN¥2.78 Billion
Bombay Dyeing & Mfg Company Limited
NSE:BOMDYEING
India Rs7.05 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Profound Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Profound Medical Corp.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.56 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Profound Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Profound Medical Corp (2014–2025)

The table below shows the annual total liabilities of Profound Medical Corp from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 CA$102.04 Million
≈ $73.81 Million
+939.91%
2024-12-31 CA$9.81 Million
≈ $7.10 Million
-22.93%
2023-12-31 CA$12.73 Million
≈ $9.21 Million
+2.53%
2022-12-31 CA$12.42 Million
≈ $8.98 Million
+101.67%
2021-12-31 CA$6.16 Million
≈ $4.45 Million
-15.09%
2020-12-31 CA$7.25 Million
≈ $5.25 Million
-53.52%
2019-12-31 CA$15.60 Million
≈ $11.28 Million
+6.65%
2018-12-31 CA$14.63 Million
≈ $10.58 Million
+33.89%
2017-12-31 CA$10.93 Million
≈ $7.90 Million
+65.80%
2016-12-31 CA$6.59 Million
≈ $4.77 Million
+26.55%
2015-12-31 CA$5.21 Million
≈ $3.77 Million
+4968.41%
2014-12-31 CA$102.73K
≈ $74.31K
--

About Profound Medical Corp

TO:PRN Canada Medical Devices
Market Cap
$272.52 Million
CA$376.73 Million CAD
Market Cap Rank
#15233 Global
#453 in Canada
Share Price
CA$10.38
Change (1 day)
+1.17%
52-Week Range
CA$5.35 - CA$12.11
All Time High
CA$35.63
About

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedb… Read more